Mechanism of cell cycle regulation by FIP200 in human breast cancer cells

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6676-6684

  Melkoumian, Zara K ^a   Peng, Xu ^a   Gan, Boyi ^a   Wu, Xiaoyang ^a   Guan, Jun Lin ^a,b  

^a Department of Obstetrics Gynecology   (United States)

^b Animal Health Diagnostic Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; DICOUMAROL; FIP200 PROTEIN; FOCAL ADHESION KINASE; OXIDOREDUCTASE INHIBITOR; PROTEASOME; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE:QUINONE OXIDOREDUCTASE I; SERINE; UBIQUITIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; CELL SPREADING; CELL STRAIN MCF 7; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; FIBROBLAST; GENE DELETION; HALF LIFE TIME; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G1 PHASE; HUMANS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-TYROSINE KINASES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 23044453057     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4142     Document Type: Article

References (47)

1. Abbi S, Ueda H, Zheng C, et al. Regulation of focal adhesion kinase by a novel protein inhibitor FIP200. Mol Biol Cell 2002;13:3178-91.
2. Chano T, Ikegawa S, Saito-Ohara F, et al. Isolation, characterization and mapping of the mouse and human RB1CC1 genes. Gene 2002;291:29-34.
3. Dahiya R, Perinchery G, Deng G, Lee C. Multiple sites of loss of heterozygosity on chromosome 8 in human breast cancer has differential correlation with clinical parameters. Int J Oncol 1998;12:811-6.
4. Chano T, Ikegawa S, Kontani K, Okabe H, Baldini N, Saeki Y. Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene 2002;21:1295-8.
5. Chano T, Kontani K, Teramoto K, Okabe H, Ikegawa S. Truncating mutations of RB1CC1 in human breast cancer. Nat Genet 2002;31:285-8.
6. Lundberg AS, Weinberg RA Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998;18:753-61.
7. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer Res Treat 1998;52:17-28.
8. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of Gj-phase progression. Genes Dev 1999;13:1501-12.
9. Dotto GP. p21 WAF1/CIP1: more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43-56.
10. Gorospe M, Wang X, Holbrook NJ. p53-dependent elevation of p2]Wafl expression by UV light is mediated through mRNA stabilization and involves a vanadate-sensitive regulatory system. Mol Cell Biol 1998;18:1400-7.
11. Timchenko NA, Harris TE, Wilde M. et al. CCAAT/enhancer binding protein α regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol 1997;17:7353-61.
12. Butz K, Geisen C, Ullmann A, Zentgraf H, Hoppe-Seyler F. Uncoupling of p21WAF1/CIP1/CDI1 mRNA and protein expression upon genotoxic sress. Oncogene 1998;17:781-7.
13. Gartel AL, Tyner AL. Transcriptional regulation of the p21WAF1/CIP1 gene. Exp Cell Res 1999;246:280-9.
14. Han DC, Guan JL. Association of focal adhesion kinase with Grb7 and its role in cell migration. J Biol Chem 1999;274:24425-30.
15. Ueda H, Abbi S, Zheng C, Guan JL. Suppression of Pyk2 kinase and cellular activities by FIP200. J Cell Biol 2000;149:423-30.
16. Sui G, Soohoo C, Affar EB, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 2002;99: 5515-20.
17. Wu X, Suetsugu S, Cooper LA, Takenawa T, Guan JL. Focal adhesion kinase regulation of N-WASP subcellular localization and function. J Biol Chem 2004;279: 9565-76.
18. Oknmura N, Saji S, Eguchi H, Hayashi S, Saji S, Nakashima S. Estradiol stabilizes p53 protein in breast cancer cell line, MCF-7. Jpn J Cancer Res 2002;93:867-73.
19. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:329-31.
20. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at Serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003;23:2171-81.
21. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiqutination and degradation by ribosomal protein L5. J Biol Chem 2004;279:44475-82.
22. Allan LA, Fried M. p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21WAF1/CIP1 repression in UV induced apoptosis. Oncogene 1999;18:5403-12.
23. Joseph TW, Zaika A, Moll UM. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regufation of the p53 response after multiple types of DNA damage. FASEB J 2003;17:1622-30.
24. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004;429:86-92.
25. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
26. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187:112-26.
27. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86-91.
28. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003;13: 49-58.
29. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7.
30. Fang S, Jensen JR Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000;275: 8945-51.
31. Kubbutat MH, Vousden KH. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 1997;17:460-8.
32. Aguilar-Lemarroy A, Gariglio P, Whitaker NJ, et al. Restoration of p53 expression sensitizes papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. Oncogene 2002;21:165-75.
33. Asher G, Lotem J, Sachs L, Kahana C, Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci U S A 2002; 99:13125-30.
34. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilized p53 through a distinct pathway. Proc Natl Acad Sci U S A 2002;99:3099-104.
35. Asher G, Tsvetkov P. Kahana C, Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 2005;19:316-21.
36. Carnero A. Targeting the cell cycle for cancer therapy. Br J Cancer 2002;87:129-33.
37. 1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 2003;22: 435-49.
38. Harbour JW, Luo RX, Santi AD, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G,. Cell 1999;98:859-69.
39. 1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
40. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E/Cdk2 activation and cell cycle reentry. Mol Cell Biol 1998;18:4499-508.
41. Bean LJ, Stark GR. Phosphorylation of serine 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV. Oncogene 2001;20: 1076-84.
42. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A 1999;96:13777-82.
43. 18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 1999;34:133-41.
44. Fuchs SY, Adler V, Buschmann T, et al. JNK targets p53 ubiquitination and degradation in noastressed cells. Genes Dev 1998;12:2658-63.
45. II31, J Biol Chem 2001;276:13852-7.
46. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003;112:779-91.
47. Grossman SR. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 2001;268: 2773-8.